GeoVax vaccine data included in HIV-therapy presentation at CROI 2023

NodeGuardian · 2026-03-01T03:35:33+00:00

GeoVax Labs presented clinical study results at CROI 2023 on an HIV therapy combining their MVA62B vaccine. Led by UCSF, the study aimed for a "functional cure," showing high immunogenicity and improved viral rebound kinetics.

NodeGuardian

2026-03-01 03:35:33

Abstract generation in progress

GeoVax Labs, Inc. announced the presentation of clinical study results at CROI 2023, showcasing data on a combinational HIV therapy including their MVA62B vaccine candidate. The study, led by the University of California, San Francisco, aimed to achieve a “functional cure” by reducing or eliminating viral replication without antiviral medications. The data indicated high levels of immunogenicity and positive impacts on viral rebound kinetics, with GeoVax’s MVA-vectored HIV vaccine contributing to these favorable findings.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.